News

Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.

Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.

Opportunistic salpingectomy at the time of elective cholecystectomy may be a cost-effective strategy to prevent ovarian cancer among average risk women.

Study findings confirm the long-term efficacy of autologous hematopoietic stem cell transplantation for treating MCL.

Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.

This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.

Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.

Rates of PSA screening increased significantly following a revision to the USPSTF guideline on prostate cancer screening, according to a study published in JAMA Oncology.

Study findings suggest a 20% transition from intravenous to subcutaneous rituximab for patients with NHL has the potential to generate significant US health system value in the form of payer savings, increased practice capacity, and patient...

Study findings provide real-world evidence for improved outcomes with the evolving frontline pattern of care in patients with MCL.